跳至主要内容

Learn about CDISC: What is CDISC? And why adopt the CDISC standard?

 

1. What is CDISC

The full name of CDISC is Clinical Data Interchange Standards Consortium, which is the Clinical Data Interchange Standards Association. It is a non-profit organization. Committed to providing data standards for the development of medical and biopharmaceutical products.

What we usually call CDISC refers to the data standard developed by this association, that is, the CDISC standard. These standards are used for the acquisition, exchange, submission and archiving of clinical and non-clinical data.

2. Why adopt the CDISC standard?

The CDISC official website lists the following benefits of implementing CIDSC standards:

Improve efficiency

Complete traceability

Enhance innovation

Improve data quality

Promote data sharing

Reduce costs

Improve predictability

Simplify the process

Let’s take a practical application scenario.

With the popularization of artificial intelligence technology, we have found that the threshold for technology application is gradually lowering, but the large enough data required to apply technology is difficult to solve in the short term.

First of all, a large amount of medical data exists in different systems and research. Due to the adoption of non-standard or standards in a certain field, these data are like information islands, which are difficult to connect and share. Secondly, within these information islands, due to the lack of unified "construction" standards, if you want to reuse it, you must know the internal "construction" details. If you want to reuse thousands of research data, the workload will undoubtedly be very large. huge.

The two problems faced above are exactly what the CDISC standard can solve.

First, develop unified data standards for the construction of data structures. Whether for humans or machines, the readability and reusability of data are greatly improved. Second, develop data exchange standards for different systems. Data exchange improves data integrity.

3. Composition of CDISC standards

The CDISC standard is constantly evolving. According to the current structure of the CDISC official website, the CDISC standard can be summarized into the following five parts:

 


CDISC family portrait

1. Foundational Standards

The basic standard is the core of the entire CDISC standard. Defines the model, domain and specification of data representation (Data Rrepresentation).

 


CDISC standards in the clinical research process

The basic standard consists of the following parts:

SEND (Standard for Exchange of Nonclinical Data)

It is the implementation standard for SDTM for non-clinical studies. SEND specifies methods for collecting and presenting non-clinical data in a consistent format.

Protocol Representation Model PRM (Protocol Representation Model)

Provide standards for the design of research protocols.

Clinical Data Acquisition Standards Harmonization (CDASH)

Content standards for data collection fields in case report forms. For example, the theme EDC system of our series should build a database in accordance with the standards of CDASH and SDTM.

Study Data Tabulation Model SDTM (Study Data Tabulation Model)

The so-called tabulation, in layman's terms, is a standard for data organization and formatting. The purpose of CDISC developing SDTM is to submit unified standard data to regulatory agencies and improve review efficiency.

Analysis Data Model ADaM (Analysis Data Model)

Establishes standards to be followed when creating analysis data sets.

BRIDG

BRIDG is a domain analysis model. The main role of BRIDG is to exchange information between medical information systems (such as HIS, LIS, and PACS) that comply with HL7 standards and clinical research systems that comply with CDISC standards. BRIDG is simultaneously a CDISC, HL7 and ISO standard.

2. Data Exchange Standards

As the name suggests, the role of data exchange standards is to exchange, share, submit and archive structured data between different systems. Data exchange standards are vendor-neutral and platform-independent. The XML mark means that the standard file format is XML (Extensible Markup Language).

Data exchange standards consist of the following standards:

ODM-XML

XML-based Schema defines content and format standards for obtaining, exchanging, submitting and archiving clinical research data in accordance with regulatory requirements. A common infrastructure is provided for Define-XML, Dataset-XML, SDM-XML and CTR-XML, and they all extend ODM-XML.

Define-XML

ODM-based metadata standard used to describe metadata for SEND, SDTM and ADaM in order to inform regulatory authorities which data sets, variables, controlled terms and other specific metadata are used.

Dataset-XML

Dataset-XML is used to describe SEND, SDTM and ADaM data sets. CDISC developed Dataset-XML with the purpose of replacing SAS V5 XPORT. Why replace it? Because it is a format standard unique to commercial companies. Dataset-XML makes some improvements over SAS V5 XPORT, removing many SAS V5 transfer file limitations (the current file format required by the FDA and PMDA), such as 8-character variable names and 200-character text field lengths. Dataset-XML and Define-XML are complementary standards, and Define-XML metadata describes the contents of the Dataset-XML data set.

CTR-XML (Clinical Trial Registry XML)

Promotes standards for the submission of clinical trial information to global clinical trial registries. Examples include the World Health Organization (WHO), the European Medicines Agency (EMA) and ClinicalTrials.gov.

SDM-XMLStudy/Trial Design Model XML

The Study/Trial Design Model is an extension of ODM that defines a machine-readable, interchangeable standard for describing clinical study design.

LAB

The LAB standard is specifically designed for the exchange of laboratory data obtained in clinical trials. Provides a standard model for the acquisition and exchange of laboratory data.

RDF (Resource Description Framework)

The full name of RDF is Resource Description Framework. It is a set of markup language technical specifications proposed by W3C, which is used to describe and express the content and structure of network resources. CDISC's RDF defines the basic standards of CDISC and is expressed in the Resource Description Framework (RDF).

3. Therapeutic Areas

It is an extension of the basic standard and develops data standards related to specific disease areas. At present, standards for more than 30 specific disease areas including Alzheimer's disease, Ebola, Parkinson's disease, asthma, etc. have been released.

4. Terminology

In brief, the Glossary explains the definitions and terminology related to the collection, exchange, and submission of data during non-clinical and clinical research phases. Contains all terms involved in the CDISC standard.

5. CDISC SHARE

The full name of SHARE is Shared Health And Research Electronic library, which is a set of tools and services. When we create databases and applications for CIDSC standards, classes, fields, and variables are manually extracted from PDFs, and SHARE facilitates the automation of standards by providing variables and other CDISC standard metadata in a machine-readable format. management and implementation.

4. Regulatory agencies and CDISC standards

Currently, FDA submissions require the following CDISC standards:

Controlled Terminology

SEND

SDTM

ADaM

Define-XML

Documents submitted by PMDA require the following CDISC standards:

SDTM

ADaM

Define-XML

Analysis Results Metadata (ARM for Define-XML)

Currently, SFDA does not require submitted documents to comply with CDISC standards.

In order to improve the quality of clinical trial data and the quality and efficiency of statistical analysis, and facilitate the exchange and summary analysis of data, when applying for new drug marketing registration, it is recommended to submit the original database and analysis database using CDISC standards.” - "Clinical Trial Data Management Work" Technical Guide

 

 

References

1. CDISC official website. https://www.cdisc.org

2.CDISC WIKI. https://en.wikipedia.org/wiki/Clinical_Data_Interchange_Standards_Consortium

3.Sam Hume.CDISC Standards Beginning to End (B2E),21-Feb-2017

4.Wayne R. Kubick.CDISC SHARE: A BRIDG-based Metadata Repository Environment

5.Giri Balasubramanian,Edwin Ponraj Thangarajan.CDISC Transport Standards - A Glance.Digital Innovation in Healthcare,8th-11th Oct 2017.

6. Wu Chongsheng, Bao Wenjun, Wang Jun, Peng Ruiling, Deng Yazhong, Zhang Zibao. Introduction to CDISC standards and their application in China [J]. Acta Pharmaceutical Sinica, 2015, 50(11): 1428-1433.

7.Samuel Hume, Anthony Chow, Julie Evans, Frederik Malfait, Julie Chason, J. Darcy Wold, Wayne Kubick, Lauren B. Becnel.CDISC SHARE, a Global, Cloud-based Resource of Machine-Readable CDISC Standards for Clinical and Translational Research.

8. Wen Tiancai, He Liyun, Liu Baoyan. BRIDG model: a bridge for the exchange of medical information and clinical research information. China Digital Medicine, 2010, 5(8):0-0.

 

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati